Influenza is a serious threat…
A healthy start today
Rea
t
othe dy to infec
rs tomorro w
…to life
3 to 5 million cases of severe influenza illness result in
250 000 to 500 000 deaths per year 1 .
…to society
The economic impact of influenza because of healthcare costs
and lost productivity is considerable 2 .
Vaccination results in a significant reduction in hospitalization due to
chronic respiratory conditions and pneumonia.
Overall mortality – a decrease of up to 50% 3
References: 1. Van de Witte SV et al. Trivalent inactivated subunit influenza vaccine Influvac ® : 30-year experience of safety and immunogenicity. Trials in Vaccinology 1 2012; pp42-48. 2. Rohde G et al.
Vaccinating High-risk Patients Against Influenza: Doing More to Protect Patients with Asthma. Annals of Respiratory Medicine 2010; 1:1-7. 3. Nichol KL et al. Influenza Vaccination and Reduction in
Hospitalizations for Cardiac Disease and Stroke among the Elderly. N Engl J Med 2003; 348:1322-1332.
S2 Influvac Subunit 2016. Composition: Each 0,5 ml Influvac Subunit 2016 influenza vaccine contains influenza virus surface antigens (haemagglutinin and neuraminidase) of strains: A/
California/7/2009 (H1N1) pdm09-like strain used (A/California/7/2009, X-181) 15 µg HA; A/Hong Kong/4801/2014 (H3N2)-like strain used (A/New Caledonia/71/2014, X-257A) 15 µg HA; B/
Brisbane/60/2008-like strain used (B/Brisbane/60/2008, wild type) 15 µg HA. Abbott Laboratories S.A. (Pty) Ltd, Reg. No. 1940/014043/07, Abbott Place, 219 Golf Club Terrace, Constantia Kloof,
1709. Tel No.: 011 858 2000 For full prescribing information refer to the package insert approved by the medicines regulatory authority. Date of publication: March 2016 Promotional Review Number:
ZAEINF150254.
Vaccinate your patients with ABBOTT’s Influvac ® this winter!